Differences in atrophy, white matter diffusion, and functional connectivity patterns have been repeatedly shown between FTD and AD patients [11–16], and between asymptomatic mutation carriers at risk for these diseases and controls (e.g., MAPT and GRN mutation carriers [29–33]; APOE4 carriers [34–43]). This evidence concerns the gene APOE and Alzheimer disease.